The latest call
FetchingFortress Biotech, Inc. reported on 13 ноября 2026 г.. We are fetching the call transcript; its summary follows once the transcript is in.
1,88 $-5,3 %закрытие 13 нояб.
The latest quarter (ended 30 сентября 2026 г.) is from Fortress Biotech’s earnings press release of 13 ноября 2026 г.. It will be replaced by the official quarterly report (10-Q) once Fortress Biotech files it.
Just reported
From Fortress Biotech, Inc.'s results release of 13 ноября 2026 г.. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
19,2M $
+8,7 % y/y
+2,4 % q/q
Guided
—
No guide given
Actual
-7,2M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| Показатель | 3 месяца по30 сент. 2026 г. | 3 месяца по30 сент. 2025 г. | Изменение |
|---|---|---|---|
| Совокупная выручка | 19,2M $ | 17,6M $ | +8,67 % |
| Прибыль | -5,8M $ | 5,9M $ | -199,91 % |
Это отдельные кварталы, а не скользящий год: цифры в остальных разделах сайта охватывают двенадцать месяцев и будут гораздо больше. Сезонный бизнес сильно колеблется между ними: ServiceNow зарабатывает 2,0 млрд $ свободного денежного потока в декабрьском квартале и 0,5 млрд $ — в июньском.
Сравнение идёт с тем же кварталом годом ранее, а не с прогнозом аналитиков. Для «превзошла» или «не дотянула» нужен консенсус-прогноз — это лицензируемые данные, которых у нас нет, и ошибиться в них хуже, чем их не приводить.
Fortress Biotech, Inc. reported on 13 ноября 2026 г.. We are fetching the call transcript; its summary follows once the transcript is in.
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Institute and Sentynl Therapeutics.
Собственное описание компании, как оно приведено в конце релиза.
The quote, the company description and the latest quarter come from Fortress Biotech’s earnings press release (an Item 2.02 8-K) filed 13 ноября 2026 г.. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Читать релиз на EDGAR Цены акций скорректированы на дробления и дивиденды.